Pro-Dex, Inc. cash flow statement PDEX

Annual Quarterly

In Q1 of fiscal 2027, the quarter ended Sep 30, 2026, Pro-Dex, Inc. generated $6.5 million of cash from operations, up 181.0% from the same quarter a year earlier. It spent $346,000 on capital expenditures. That left free cash flow of $6.1 million. The company returned $600,000 in share buybacks to shareholders.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q1 FY2027 Sep 30, 2026	Q4 FY2026 Jun 30, 2026	Q3 FY2026 Mar 31, 2026	Q2 FY2026 Dec 31, 2025	Q1 FY2026 Sep 30, 2025	Q4 FY2025 Jun 30, 2025	Q3 FY2025 Mar 31, 2025	Q2 FY2025 Dec 31, 2024
Operating
Depreciation and amortization	1 +19.1%	0 +29.6%	0 +29.3%	0 +17.1%	0 +0.3%	0 +3.0%	0 +2.6%	0 +8.4%	0 +9.8%
Stock-based compensation	1 +9.8%	0 -16.1%	0 +14.9%	0 +17.7%	0 +26.2%	0 +42.5%	0 +805.9%	0 -21.8%	0 -34.3%
Operating cash flow	11 +1007.2%	6 +181.0%	-0 -57.8%	2 +116.6%	4 +186.1%	2 +22.4%	-0 -116.6%	1 -81.5%	-4 -684.5%
Investing
Capital expenditures	1	0 +253.1%	0	0 -37.8%	0 -87.1%	0 -77.3%	—	0 +53.8%	1 -14.4%
Investing cash flow	4 +3757.9%	-0 -253.1%	0 +120.0%	-5 -392.7%	9 +1736.2%	-0 +77.3%	-1 -827.1%	2 +1576.1%	-1 +71.2%
Financing
Debt issued	—	—	—	—	—	—	—	4	4 +250.0%
Stock buybacks	2	1 -74.0%	1	1	0 -97.0%	—	0 -100.0%	0 -100.0%	4 +1318.6%
Financing cash flow	-4 -173.8%	-3 -21.7%	-2 +40.3%	5 +183.6%	-5 -398.2%	-2 -110.4%	-3 -89.3%	2 +194.9%	2 +200.5%
Change in cash
Free cash flow	11	6 +177.8%	-0	2 +165.0%	4 +174.6%	2 +51.9%	—	1 -85.5%	-5 -6193.5%
Per share
Free cash flow per share	3.23	1.85 +179.7%	-0.14	0.47 +170.5%	1.06 +175.4%	0.66 +49.8%	—	0.17 -84.7%	-1.41 -6694.5%
Shareholder returns
Returned to shareholders	2	1	1	1	0	—	0	0	4
Share of free cash flow	15.87%	9.77%	—	39.51%	2.97%	—	—	0.00%	—
Ratios
Free cash flow margin	13.43%	29.88%	-2.33%	7.62%	18.76%	11.94%	—	3.30%	-27.94%
Capital expenditures to revenue	0.92%	1.68%	0.99%	0.56%	0.38%	0.53%	—	1.03%	3.23%
Stock-based compensation to revenue	0.83%	0.66%	0.87%	0.93%	0.88%	0.87%	0.88%	0.91%	0.77%
Cash conversion	0.95x	2.13x	-0.10x	0.41x	1.63x	0.49x	-0.14x	0.23x	-2.03x

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as: PDEX (Nasdaq)
Fiscal year ends: June 30
Headquarters: Irvine, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 788920

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.